- Home
- KAVL vs VIVS Comparison
KAVL vs VIVS Comparison
Compare KAVL & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KAVL | VIVS |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 8.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KAVL | VIVS |
|---|---|---|
| Price | $0.47 | $2.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 62.5K | 59.7K |
| Earning Date | 09-16-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,127,037.00 | $140,000.00 |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 35.92 |
| 52 Week Low | $0.40 | $1.41 |
| 52 Week High | $1.55 | $21.96 |
Technical Indicators
Market Signals| Indicator | KAVL | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 41.41 | 42.85 |
| Support Level | $0.46 | $2.12 |
| Resistance Level | $0.50 | $2.35 |
| Average True Range (ATR) | 0.04 | 0.16 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 15.60 | 26.61 |
Price Performance
Historical ComparisonAbout KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating creative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.